Abstract
Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) have shown poor efficacy in patients (pts) With non-small-cell lung cancer (NSCLC) Harboring uncommon EGFR Mutations. We aim to explore the efficacy and safety of third-generation TKI Aumolertinib in EGFR-uncommon mutant NSCLC pts.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
